Krishna Institute of Medical Sciences (KIMS)₹721.65−1.78%Hospital
In the Jun 2026 quarter (consolidated), Krishna Institute of Medical Sciences reported sales of ₹1,182 Cr, up 35.3% from Jun 2025, and net profit of ₹36.98 Cr, down 56.4% year on year. For the year to Mar 2026, sales were ₹3,910 Cr and net profit ₹242 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 653 | 607 | 635 | 689 | 778 | 773 | 798 | 873 | 963 | 1,000 | 1,076 | 1,182 |
| Expenses | 476 | 460 | 476 | 510 | 561 | 586 | 601 | 681 | 758 | 802 | 870 | 959 |
| Operating Profit | 177 | 147 | 159 | 178 | 217 | 187 | 198 | 192 | 203 | 199 | 205 | 222 |
| OPM % | 26.9% | 23.9% | 24.9% | 26.0% | 28.0% | 24.0% | 25.0% | 22.0% | 21.0% | 20.0% | 19.0% | 18.9% |
| Other Income | 2.99 | 2.99 | 3.99 | 4.99 | 4.99 | 17.95 | 14.97 | 6.99 | 3.99 | 4.99 | 0.99 | 16.95 |
| Interest | 9.01 | 11.99 | 15.99 | 17.99 | 20.01 | 25.97 | 27.01 | 32.98 | 44.98 | 57.03 | 67.98 | 82.98 |
| Depreciation | 32.94 | 34.90 | 45.89 | 38.92 | 40.89 | 44.89 | 52.86 | 52.91 | 65.85 | 78.79 | 84.80 | 101 |
| Profit before tax | 139 | 102 | 99.73 | 127 | 162 | 135 | 134 | 114 | 96.72 | 68.75 | 54.81 | 56.80 |
| Tax % | 27.0% | 25.0% | 28.0% | 25.0% | 26.0% | 31.0% | 21.0% | 25.0% | 26.0% | 24.0% | 40.0% | 34.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89 | 0.00 | −0.29 | 0.00 | −3.96 | 0.00 |
| Net Profit | 101 | 76.89 | 71.90 | 94.94 | 121 | 91.93 | 106 | 84.90 | 71.92 | 51.91 | 32.95 | 36.98 |
| EPS (Rs) | 2.29 | 1.81 | 1.65 | 2.15 | 2.69 | 2.21 | 2.55 | 1.97 | 1.68 | 1.32 | 1.07 | 1.00 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 513 | 568 | 665 | 919 | 1,125 | 1,333 | 1,653 | 2,201 | 2,503 | 3,037 | 3,910 | 4,221 |
| Expenses | 404 | 451 | 595 | 835 | 874 | 955 | 1,128 | 1,591 | 1,855 | 2,248 | 3,098 | 3,389 |
| Operating Profit | 109 | 118 | 70.86 | 84.71 | 250 | 376 | 523 | 610 | 646 | 791 | 812 | 830 |
| OPM % | 21.0% | 21.0% | 10.9% | 9.0% | 22.0% | 28.0% | 31.9% | 27.9% | 25.9% | 26.0% | 21.0% | 19.7% |
| Other Income | 4.99 | 2.99 | 36.93 | 5.99 | 4.99 | 8.98 | 26.94 | 40.94 | 12.98 | 42.91 | 16.95 | 26.92 |
| Interest | 36.97 | 31.98 | 87.95 | 49.02 | 43.99 | 36.98 | 21.99 | 37.01 | 54.98 | 100 | 215 | 253 |
| Depreciation | 35.93 | 34.93 | 39.93 | 55.88 | 70.91 | 69.92 | 72.90 | 129 | 147 | 177 | 282 | 330 |
| Profit before tax | 40.86 | 52.81 | −19.95 | −14.95 | 141 | 278 | 455 | 484 | 459 | 557 | 333 | 277 |
| Tax % | 32.0% | 37.0% | 126.0% | 223.0% | 18.0% | 26.0% | 25.0% | 25.0% | 27.0% | 26.0% | 28.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.99 | −0.99 | −1.99 | 11.95 | 1.99 | 33.89 | −6.97 | −4.25 |
| Net Profit | 27.96 | 32.96 | −45.95 | −48.97 | 115 | 205 | 343 | 365 | 336 | 414 | 242 | 194 |
| EPS (Rs) | 0.77 | 0.92 | −1.33 | −1.29 | 3.19 | 5.20 | 8.31 | 8.42 | 7.76 | 9.62 | 6.04 | 5.07 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70.19 | 72.18 | 50.19 | 74.08 | 74.06 | 78.08 | 80.05 | 80.07 | 80.22 | 80.26 | 80.09 |
| Reserves | 193 | 255 | −210 | 466 | 524 | 786 | 1,306 | 1,591 | 1,749 | 2,061 | 2,168 |
| Borrowings | 255 | 279 | 751 | 335 | 368 | 315 | 256 | 675 | 1,352 | 2,555 | 4,241 |
| Other Liabilities | 145 | 166 | 359 | 236 | 227 | 252 | 259 | 550 | 633 | 987 | 1,184 |
| Total Liabilities | 664 | 773 | 952 | 1,112 | 1,191 | 1,431 | 1,901 | 2,897 | 3,815 | 5,682 | 7,674 |
| Fixed Assets | 514 | 517 | 752 | 860 | 913 | 928 | 1,002 | 1,761 | 2,428 | 3,340 | 5,692 |
| CWIP | 2.01 | 63.98 | 0.00 | 0.00 | 1.99 | 9.01 | 20.99 | 477 | 600 | 1,213 | 606 |
| Investments | 10.99 | 14.01 | 0.00 | 0.00 | 0.00 | 0.00 | 332 | 67.94 | 157 | 98.97 | 103 |
| Other Assets | 137 | 177 | 199 | 250 | 276 | 494 | 547 | 590 | 629 | 1,030 | 1,272 |
| Inventories | 11.99 | 16.01 | 19.99 | 27.01 | 30.02 | 24.01 | 36.01 | 43.01 | 48.99 | 64.02 | 97.03 |
| Trade receivables | 65.92 | 91.81 | 108 | 123 | 132 | 110 | 129 | 253 | 294 | 395 | 553 |
| Cash & equivalents | 7.01 | 8.02 | 11.02 | 10.01 | 46.09 | 285 | 190 | 66.16 | 49.09 | 80.12 | 75.14 |
| Total Assets | 664 | 773 | 952 | 1,112 | 1,191 | 1,431 | 1,901 | 2,897 | 3,815 | 5,682 | 7,674 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 94.90 | 81.89 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 | 511 |
| Cash from investing activity | −41.04 | −100 | −64.03 | −110 | −125 | −355 | −412 | −416 | −754 | −1,117 | −1,455 |
| Cash from financing activity | −64.80 | 23.93 | −38.86 | −26.92 | −43.87 | 9.96 | 60.80 | 19.95 | 216 | 541 | 937 |
| Net cash flow | −11.01 | 5.01 | 3.01 | −2.99 | 31.98 | 11.99 | −25.98 | 35.99 | −15.01 | 9.01 | −0.99 |
| Capex | 34.95 | 99.77 | 58.92 | 76.87 | 51.91 | 93.86 | 170 | 574 | 646 | 1,007 | 1,425 |
| Free cash flow | 61.06 | −18.01 | 49.07 | 57.04 | 150 | 262 | 154 | −140 | −125 | −380 | −904 |
| CFO / OP % | 88.0% | 80.1% | 192.1% | 195.0% | 102.1% | 104.0% | 86.1% | 87.1% | 102.0% | 91.1% | 81.1% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 47 | 59 | 59 | 49 | 43 | 30 | 28 | 42 | 43 | 48 | 52 |
| Inventory days | 37 | 44 | 47 | 48 | 45 | 31 | 38 | — | — | — | — |
| Days payable | 195 | 208 | 216 | 182 | 178 | 168 | 134 | — | — | — | — |
| Cash conversion cycle | −111 | −105 | −110 | −85 | −91 | −106 | −67 | 42 | 43 | 48 | 52 |
| Working capital days | 12 | 27 | −332 | −14 | −14 | −30 | −2 | 9 | −4 | −28 | −36 |
| ROCE % | — | 15.0% | 11.0% | 5.0% | 20.0% | 29.0% | 34.0% | 24.0% | 17.0% | 15.0% | 10.0% |
For the Jun 2026 quarter, Krishna Institute of Medical Sciences reported sales of ₹1,182 Cr, up 35.3% year on year and net profit of ₹36.98 Cr, down 56.4% year on year. The operating margin was 18.9%.
Krishna Institute of Medical Sciences' sales for the year to Mar 2026 were ₹3,910 Cr; over the last twelve months they were ₹4,221 Cr.
Net profit for the year to Mar 2026 was ₹242 Cr, and ₹194 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.07.
Krishna Institute of Medical Sciences reported borrowings of ₹4,241 Cr at Mar 2026, against cash and equivalents of ₹75.14 Cr.
Cash from operations was ₹511 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹904 Cr.